WCRX

BRIEF-Warner Chilcott reports quarterly results - 11/10 - 07:16 AM ET

WARNER CHILCOTT STILL SEES 2008 REV $935M-$945M; TR AVG REV EST $939.8M - 08/08 - 07:06 AM ET

WARNER CHILCOTT 2Q REV $234.2M VS YEAR AGO $227M; TR AVG REV EST $230.6M - 08/08 - 07:05 AM ET

WARNER CHILCOTT 2Q NET EARNINGS $33.6M, OR 13C/SHARE VS YEAR AGO EPS 3C - 08/08 - 07:04 AM ET

WARNER CHILCOTT 2Q ADJ CASH EPS $84.3M - 08/08 - 07:04 AM ET

WARNER CHILCOTT 2Q TR AVG EPS EST 32C - 08/08 - 07:04 AM ET

WCRX touches 50-day moving average at 17.35 - 07/08 - 10:39 AM ET

Warner Chilcott granted approval for acne drug - 06/24 - 08:29 AM ET

Warner Chilcott Limited receives FDA approval for DORYX Delayed-Release tablets, 150 mg - 06/24 - 07:21 AM ET

Warner Chilcott gets FDA approval for 150 mg Doryx tablets - 06/23 - 08:45 AM ET

WARNER CHILCOTT'S SEVERE ACNE TREATMENT DORYX 150MG TABLETS APPROVED BY FDA - 06/23 - 08:33 AM ET

Research and Markets: Warner Chilcott Ltd has a Strong Portfolio of Marketed and Pipeline Products Specialising in Women's Health and Dermatology - 06/09 - 09:29 AM ET

Research and Markets: Warner Chilcott Ltd has a Strong Portfolio of Marketed and Pipeline Products Specialising in Womens Health and Dermatology - 06/09 - 09:27 AM ET

Warner Chilcott and Leo Pharma obtain FDA approval for Taclonex Scalp - 05/13 - 06:27 AM ET

Hi-Tech Pharmacal signs supply agreement with Warner Chilcott's subsidiary - 05/12 - 12:46 PM ET

Warner Chilcott Q1 revenues rise - 05/12 - 12:42 PM ET

FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis - 05/12 - 09:09 AM ET

Warner Chilcott swings to 1Q profit; revenue rises above expectations - 05/09 - 06:58 AM ET

WARNER CHILCOTT SEES 2008 EPS BETWEEN $1.30 AND $1.45 A SHARE - 05/09 - 06:45 AM ET

WARNER CHILCOTT STILL SEES 2008 REV BETWEEN $935M AND $945M - 05/09 - 06:43 AM ET

Page 1 of 3     1  2   3      Previous  |  Next

<< Back to Stock Index